Vascular gene transfer for the treatment of restenosis and atherosclerosis

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 465-469

  Laitinen, Marja ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FIBROBLAST GROWTH FACTOR; LIPOPROTEIN; NITRIC OXIDE SYNTHASE; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ADVENTITIA; ANGIOGENESIS; ANGIOPLASTY; ARTERY WALL; ATHEROSCLEROSIS; CLINICAL TRIAL; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HOMEOBOX; HUMAN; HYPERLIPOPROTEINEMIA; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; RESTENOSIS; REVIEW; SAFETY;

ANGIOPLASTY; ARTERIOSCLEROSIS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERLIPIDEMIAS;

ANIMALIA;

EID: 0031731473     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00011     Document Type: Review

References (61)

1. Ross R. Pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
2. Nikol S, Huehns TY, Hofling B. Molecular biology and postangioplasty restenosis. Atherosclerosis 1996; 123:17-31.
3. Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repealed Thromboxane Antagonism Study (CARPORT). Circulation 1991;84:1568-1580.
4. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994; 330:981-983.
5. Herrman JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail. Drugs 1993; 46:18-52.
6. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991; 84:1426-1436.
7. Califf RM. Restenosis: the cost to society. Am Heart J 1995; 130:680-684.
8. Grondin CM, Campeau L, Lespérance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and sub-venous vein grafts in two consecutive series. Circulation 1984; 70:208-212.
9. Sigwart U. Endovascular stents. Science Med 1997; (Sept/Oct):16-25.
10. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx Glmunrle, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-495.
11. Fischman DL, Leon MB, Baim DS, Schatz RA. Savage MP, Nann I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496-501.
12. Narins CR, Holmes DR, Topol EJ. A call for provisional sterling. The balloon is back! Circulation 1998; 97:1298-1305.
13. Libby P. Gene therapy of restenosis. Promise and perils. Circ Res 1998: 82:404-406.
14. Sanghong B, March KL. Gene therapy for restenosis. Getting nearer the heart of the matter. Circ Res 1998; 82:295-305. An excellent review about the possibilities of vascular gene therapy.
15. De Young MB, Dichek DA. Gene therapy for restenosis. Are we ready? Circ Res 1998; 82:306-313. A critical review about vascular gene therapy.
16. Boulikas T. An overview on gene therapy. Gene therapy and molecular biology 1998; 1:1-171. An extensive overview of gene therapy.
17. Laitinen M, Zachary I, Breier G, Pakkanen T, Häkkinen T, Luoma J, et al. VEGF gene transfer reduces intimai thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997; 8:1737-1744.
18. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS-Lett 1997; 420:28-32.
19. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95:1030-1037.
20. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97:99-107.
21. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997; 8:879-886.
22. Korpelainen El, Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998; 10:159-164.
23. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, et al. Gene transfer into the carotid artery using an adventitial collar: Comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997; 8:1645-1650.
24. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2:534-539.
25. Ueno H, Li JJ, Masuda S, Qi Z, Yamamoto H, Takeshita A. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997; 17:2453-2460.
26. Tabata H, Silver M, Isner JM. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997; 35:470-479.
27. Nabel EG, Yang Z, Plautz G, Forough R, Zhan X, Haudenschild CC, et al. Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362:844-846.
28. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-650. First evidence that intramyocardial injection of recombinant FGF protein induces angiogenesis in vivo.
29. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-1169.
30. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180.
31. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60.
32. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; 97:381-390.
33. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy tor vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265:781-784.
34. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994; 91:10732-10736.
35. Chang MW, Barr E, Selter J, Jiang YQ, Nabel GJ, Nabel EG, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267:518-522.
36. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 2:222-227.
37. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K, Sueishi K. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998; 82:147-156.
38. Muller DW. The role of proto-oncogenes in coronary restenosis. Prog Cardiovasc Dis 1997; 40:117-128.
39. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82:1023-1028.
40. Mann M, Whittemore A, Donaldson MC, Belkin MA, Orav EJ, Polak J, Dzau VJ. Preliminary experience with genetic engineering of human vein grafts: Evidence for target gene inhibition. Circulation 1997; 96:1-4, 20 (abstract).
41. Smith R, Branellec D, Gorski D, Quo K, Perlman H, Dedieu J, et al. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev 1997; 11:1674-1689.
42. Skopicki H, Lyons G, Schatteman G, Smith R, Andres V, Schirm S, lsner J, Walsh K. Embryonic expression of the Gax homeodomain protein in cardiac, smooth, and skeletal muscle. Circ Res 1997; 80:452-462.
43. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101:1478-1487.
44. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92:1137-1141.
45. Kullo IJ, Schwartz RS, Pompili VJ, Tsutsui M, Milstien S, Fitzpatrick LA, et al. Expression and function of recombinant endothelial NO synthase in coronary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2405-2412.
46. Rutherford C, Martin W, Salame M, Carrier M, Änggård E, Ferns G. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 1997; 130:45-51.
47. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe Heritable Hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269:13695-13702.
48. Pakkanen T, Laitinen M, Hippeläinen M, Kallionpaa H, Lehtolainen P, Leppänen P, et al. Enhanced plasma cholesterol lowering effect of retro-virus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase-ganciclovir treatment. Atherosclerosis 1997; 134:42.
49. Grossman M, Rader DJ, Muller DWM. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148-1154.
50. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387:414-417.
51. Zsigmond E, Kobayashi K, Tzung KW, Li I, Fuke Y, Chan L. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther 1997; 8:1921-1933.
52. Excoffon KJ, Liu G, Miao L, Wilson JE, McManus BM, Semenkovich CF. Correction of hypertriglyceridemiaand impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol 1997; 17:2532-2539.
53. Yla-Herttuala S. Vascular gene transfer. Curr Opin Lipidol 1997; 8:72-76.
54. Rome JJ, Shayani V, Flugelman MY, Newman KD, Farb A, Virmani R, Dichek DA. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Arterioscler Thromb 1994; 14:148-161.
55. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, Mc Garr SE. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995; 95:2662-2671.
56. Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal R. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischaemia. Hum Gene Ther 1998; 9:1481-1486. First evidence that gene transfer occurs in human atherosclerotic arteries in vivo.
57. Camenzind E, Kint PP, Carlo Di Mario RN. Intracoronary heparin delivery in humans. Circulation 1995; 92:2363-2472.
58. Feldman LJ, Steg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997; 35:391-404.
59. Svensson EC, Black HB, Dugger DL, Tripathy SK, Goldwasser E, Hao Z, et al. Long-term erythropoietin expression in rodents and nonhuman primates following intramuscular injection of a replication-defective adeno-viral vector. Hum Gene Ther 1997; 8:1797-1806.
60. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5:40-49.
61. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114-1123. First results of VEGF gene transfer in peripheral artery disease in man.